High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. (2002)
- Authors:
- USP affiliated authors: CARRILHO, FLAIR JOSE - FM ; NITA, SUZANE KIOKO ONO - FM ; SILVA, LUIZ CAETANO DA - FM
- Unidade: FM
- Subjects: HEPATOPATIAS; RNA
- Language: Inglês
- Imprenta:
- Conference titles: Therapies for viral hepatitits
-
ABNT
SILVA, L. C. da et al. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002, Anais.. Boston,: Faculdade de Medicina, Universidade de São Paulo, 2002. . Acesso em: 24 abr. 2024. -
APA
Silva, L. C. da, Nita, S. K. O., Madruga, C. L., Carrilho, F. J., Bassit, L., Pinho, J. R. R., et al. (2002). High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. In . Boston,: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Silva LC da, Nita SKO, Madruga CL, Carrilho FJ, Bassit L, Pinho JRR, Mello IMVGC, Malta FM, Yamaguchi M. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002 ;[citado 2024 abr. 24 ] -
Vancouver
Silva LC da, Nita SKO, Madruga CL, Carrilho FJ, Bassit L, Pinho JRR, Mello IMVGC, Malta FM, Yamaguchi M. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002 ;[citado 2024 abr. 24 ] - High resistance to therapy in cirrhotic patients carrying HCV-RNA genotype 3
- Rapid and profound drop HCV RNA viremia induced by high dose of consensus IFN (CIFN) just before starting pegylated interferon (PEG-IFN) plus ribavirin (RBV) in chronic hepatitits C patients (pts) previously resistant to combined therapy (IFN+RBV): preliminary report
- Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon
- Tratamento da hepatite C
- Rapid and profound drop of HCV RNA viraemia induced by high dose of consensus interferon just before starting pegylated interferon plus ribavirin in chronic hepatitis C patients previously resistant to combined therapy:: preliminary report.
- A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response.
- A prospective study of the prevalence of hepatitis B and C virus co-infection among patients with chronic renal disease under hemodialysis
- Searching for chronic hepatitis B patients in a low prevalence area: role of racial origin
- A phylogenetic study of hepatitis B virus in chronically infected Brazilian patients of Western and Asian descent
- Cinética viral e resultados tardios do tratamento com consensus interferon a (CIFN) e ribavirina (RB) em pacientes com hepatite crônica C (HC-C) previamente resistentes à associação com IFN a e RB
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
